Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 487


Screening, diagnosis and risks associated with Hepatitis E virus infection.

Lhomme S, Legrand-Abravanel F, Kamar N, Izopet J.

Expert Rev Anti Infect Ther. 2019 Jun;17(6):403-418. doi: 10.1080/14787210.2019.1613889. Epub 2019 May 13.


An open-label, randomized trial indicates that everolimus with tacrolimus or cyclosporine is comparable to standard immunosuppression in de novo kidney transplant patients.

Sommerer C, Suwelack B, Dragun D, Schenker P, Hauser IA, Witzke O, Hugo C, Kamar N, Merville P, Junge M, Thaiss F, Nashan B; Athena Study Group.

Kidney Int. 2019 Feb 27. pii: S0085-2538(19)30193-0. doi: 10.1016/j.kint.2019.01.041. [Epub ahead of print]


Pharmacokinetics and Pharmacodynamics of Once-daily Prolonged-release Tacrolimus in Liver Transplant Recipients.

Allard M, Puszkiel A, Conti F, Chevillard L, Kamar N, Noé G, White-Koning M, Thomas-Schoemann A, Simon T, Vidal M, Calmus Y, Blanchet B.

Clin Ther. 2019 May;41(5):882-896.e3. doi: 10.1016/j.clinthera.2019.03.006. Epub 2019 Apr 17.


No evidence of occult hepatitis C or E virus infections in liver-transplant patients with sustained virological response after therapy with direct acting agents.

Del Bello A, Abravanel F, Alric L, Lavayssiere L, Lhomme S, Bellière J, Izopet J, Kamar N.

Transpl Infect Dis. 2019 Apr 11:e13093. doi: 10.1111/tid.13093. [Epub ahead of print]


Hepatitis B virus reactivation in transplant patients treated for hepatitis C recurrence: Prophylaxis makes the difference.

Mouna L, Rossignol E, Tateo M, Coilly A, Duclos-Vallée JC, Duvoux C, Durand F, Tran A, Radenne S, Canva-Delcambre V, Houssel-Debry P, Dumortier J, Conti F, de Ledinghen V, Leroy V, Kamar N, Di Martino V, Moreno C, Botta Fridlund D, d'Alteroche L, Lebray P, Perre P, Besch C, Silvain C, Habersetzer F, Debette-Gratien M, Abergel A, Diallo A, Samuel D, Roque-Afonso AM, Pageaux GP; ANRS CO23 CUPILT study group.

J Hepatol. 2019 Jun;70(6):1297-1300. doi: 10.1016/j.jhep.2019.02.019. Epub 2019 Apr 6. No abstract available.


Epitope load identifies kidney transplant recipients at risk of allosensitization following minimization of immunosuppression.

Snanoudj R, Kamar N, Cassuto E, Caillard S, Metzger M, Merville P, Thierry A, Jollet I, Grimbert P, Anglicheau D, Hazzan M, Choukroun G, Hurault De Ligny B, Janbon B, Vuiblet V, Devys A, Le Meur Y, Delahousse M, Morelon E, Bailly E, Girerd S, Amokrane K, Legendre C, Hertig A, Rondeau E, Taupin JL.

Kidney Int. 2019 Jun;95(6):1471-1485. doi: 10.1016/j.kint.2018.12.029. Epub 2019 Mar 5.


Percutaneous transluminal angioplasty alone versus stent placement for the treatment of transplant renal artery stenosis.

Macchini M, Mokrane T, Darcourt J, Bellière J, Kamar N, Candelari R, Rousseau H, Meyrignac O.

Diagn Interv Imaging. 2019 Apr 2. pii: S2211-5684(19)30068-3. doi: 10.1016/j.diii.2019.03.010. [Epub ahead of print]


Seroprevalence of hepatitis E virus (HEV) in a general adult population in Northern Norway: the Tromsø study.

Olsøy IB, Henriksen S, Weissbach FH, Larsen M, Borgen K, Abravanel F, Kamar N, Paulssen EJ, Hirsch HH, Rinaldo CH.

Med Microbiol Immunol. 2019 Mar 22. doi: 10.1007/s00430-019-00599-5. [Epub ahead of print]


Control of replication of hepatitis B and C virus improves patient and graft survival in kidney transplantation.

Fontaine H, Alric L, Labreuche J, Legendre B, Louvet A, Antoine C, Legendre CM, Hazzan M, Kamar N, Dharancy S, Pol S, Duhamel A, Mathurin P.

J Hepatol. 2019 May;70(5):831-838. doi: 10.1016/j.jhep.2018.12.036. Epub 2019 Mar 14.


[Hepatitis E virus infection].

Marion O, Izopet J, Kamar N.

Rev Prat. 2018 Mar;68(3):286-290. French.


Should 12- or 24-week post-ribavirin follow-up be considered to define sustained virological response in transplant patients treated for chronic hepatitis E virus infection?

Marion O, Lhomme S, Abravanel F, Izopet J, Kamar N.

Transpl Infect Dis. 2019 Jun;21(3):e13065. doi: 10.1111/tid.13065. Epub 2019 Mar 22. No abstract available.


Dynamic predictions of long-term kidney graft failure: an information tool promoting patient-centred care.

Fournier MC, Foucher Y, Blanche P, Legendre C, Girerd S, Ladrière M, Morelon E, Buron F, Rostaing L, Kamar N, Mourad G, Garrigue V, Couvrat-Desvergnes G, Giral M, Dantan E; DIVAT Consortium.

Nephrol Dial Transplant. 2019 Mar 11. pii: gfz027. doi: 10.1093/ndt/gfz027. [Epub ahead of print]


Early Acute Microvascular Kidney Transplant Rejection in the Absence of Anti-HLA Antibodies Is Associated with Preformed IgG Antibodies against Diverse Glomerular Endothelial Cell Antigens.

Delville M, Lamarthée B, Pagie S, See SB, Rabant M, Burger C, Gatault P, Giral M, Thaunat O, Arzouk N, Hertig A, Hazzan M, Matignon M, Mariat C, Caillard S, Kamar N, Sayegh J, Westeel PF, Garrouste C, Ladrière M, Vuiblet V, Rivalan J, Merville P, Bertrand D, Le Moine A, Van Huyen JPD, Cesbron A, Cagnard N, Alibeu O, Satchell SC, Legendre C, Zorn E, Taupin JL, Charreau B, Anglicheau D.

J Am Soc Nephrol. 2019 Apr;30(4):692-709. doi: 10.1681/ASN.2018080868. Epub 2019 Mar 8.


Impact of estimation versus direct measurement of predonation glomerular filtration rate on the eligibility of potential living kidney donors.

Gaillard F, Courbebaisse M, Kamar N, Rostaing L, Jacquemont L, Hourmant M, Del Bello A, Couzi L, Merville P, Malvezzi P, Janbon B, Moulin B, Maillard N, Dubourg L, Lemoine S, Garrouste C, Pottel H, Legendre C, Delanaye P, Mariat C.

Kidney Int. 2019 Apr;95(4):896-904. doi: 10.1016/j.kint.2018.11.029. Epub 2019 Feb 26.


No Clear Evidence for an Effect of Sofosbuvir Against Hepatitis E Virus in Organ Transplant Patients.

Kamar N, Pan Q.

Hepatology. 2019 Apr;69(4):1846-1847. doi: 10.1002/hep.30546. Epub 2019 Mar 18. No abstract available.


Failure to respond to ribavirin despite elevated intra-erythrocyte zinc level in transplant-patients with chronic hepatitis E virus infection.

Marion O, Abravanel F, Izopet J, Kamar N.

Transpl Infect Dis. 2019 Apr;21(2):e13050. doi: 10.1111/tid.13050. Epub 2019 Feb 4. No abstract available.


Hepatitis E virus genotype 3 and capsid protein in the blood and urine of immunocompromised patients.

Marion O, Capelli N, Lhomme S, Dubois M, Pucelle M, Abravanel F, Kamar N, Izopet J.

J Infect. 2019 Mar;78(3):232-240. doi: 10.1016/j.jinf.2019.01.004. Epub 2019 Jan 17.


The Effectiveness of Topical Cerium Nitrate-Silver Sulfadiazine Application on Overall Outcome in Patients with Calciphylaxis.

Darres A, Delaval R, Fournier A, Tournier E, Cointault O, Moussion F, Chauveau D, Seigneuric B, Lumbroso C, Kamar N, Ribes D, Leou S, Huart A, Testevuide P, Faguer S.

Dermatology. 2019;235(2):120-129. doi: 10.1159/000493975. Epub 2019 Jan 3.


Incidence of Donor-Specific Anti-HLA Antibodies in Non-HLA-Sensitized Patients Given Tacrolimus Once or Twice Daily During the First 2 Years After Kidney Transplant.

Hage V, Ferrandiz I, Béllière J, Esposito L, Hebral AL, Cointault O, Del Bello A, Kamar N.

Exp Clin Transplant. 2019 Jun;17(3):313-319. doi: 10.6002/ect.2018.0043. Epub 2018 Dec 31.


Monitoring hepatitis E virus fecal shedding to optimize ribavirin treatment duration in chronically infected transplant patients.

Marion O, Lhomme S, Del Bello A, Abravanel F, Esposito L, Hébral AL, Lavayssière L, Cointault O, Ribes D, Izopet J, Kamar N.

J Hepatol. 2019 Jan;70(1):206-209. doi: 10.1016/j.jhep.2018.09.011. Epub 2018 Oct 24. No abstract available.


Pharmacokinetics of Prolonged-Release Once-Daily Formulations of Tacrolimus in De Novo Kidney Transplant Recipients: A Randomized, Parallel-Group, Open-Label, Multicenter Study.

Kamar N, Cassuto E, Piotti G, Govoni M, Ciurlia G, Geraci S, Poli G, Nicolini G, Mariat C, Essig M, Malvezzi P, Le Meur Y, Garrigue V, Del Bello A, Rostaing L.

Adv Ther. 2019 Feb;36(2):462-477. doi: 10.1007/s12325-018-0855-1. Epub 2018 Dec 14.


Robot-assisted laparoscopic partial nephrectomy with renal artery clamping using an endovascular balloon catheter for an allograft kidney tumor: A new perspective to manage renal vascular control?

Laclergerie F, Delchier MC, Covin B, Sallusto F, Soulie M, Gamé X, Beauval JB, Kamar N, Roumiguié M, Doumerc N.

Am J Transplant. 2019 Apr;19(4):1239-1240. doi: 10.1111/ajt.15151. Epub 2018 Nov 10. No abstract available.


Do natural antibodies have a detrimental effect after kidney transplantation?

Del Bello A, Kamar N.

Ann Transl Med. 2018 Aug;6(16):316. doi: 10.21037/atm.2018.07.10. No abstract available.


Performance of a commercial assay for detecting and quantifying HEV RNA in faeces.

Abravanel F, Lacipière A, Lhomme S, Dubois M, Minier L, Peron JM, Alric L, Kamar N, Izopet J.

J Clin Virol. 2018 Dec;109:1-5. doi: 10.1016/j.jcv.2018.10.003. Epub 2018 Oct 10.


Executive summary of the 2018 KDIGO Hepatitis C in CKD Guideline: welcoming advances in evaluation and management.

Jadoul M, Berenguer MC, Doss W, Fabrizi F, Izopet J, Jha V, Kamar N, Kasiske BL, Lai CL, Morales JM, Patel PR, Pol S, Silva MO, Balk EM, Gordon CE, Earley A, Di M, Martin P.

Kidney Int. 2018 Oct;94(4):663-673. doi: 10.1016/j.kint.2018.06.011.


The age-calibrated measured glomerular filtration rate improves living kidney donation selection process.

Gaillard F, Courbebaisse M, Kamar N, Rostaing L, Del Bello A, Girerd S, Kessler M, Flamant M, Vidal-Petiot E, Peraldi MN, Couzi L, Merville P, Malvezzi P, Janbon B, Moulin B, Caillard S, Gatault P, Büchler M, Maillard N, Dubourg L, Roquet O, Garrouste C, Legendre C, Delanaye P, Mariat C.

Kidney Int. 2018 Sep;94(3):616-624. doi: 10.1016/j.kint.2018.05.016.


Tacrolimus Granules for Oral Suspension as Post-Transplant Immunosuppression in Routine Medical Practice in France: The OPTIMOD Study.

Garaix F, Stern M, Lamy FX, Dubel L, Kamar N.

Ann Transplant. 2018 Aug 10;23:561-571. doi: 10.12659/AOT.908522.


Comparison of graft and patient survival according to the transplantation centre policy for 1-year screening biopsy among stable kidney recipients: a propensity score-based study.

Couvrat-Desvergnes G, Foucher Y, Le Borgne F, Dion A, Mourad G, Garrigue V, Legendre C, Rostaing L, Kamar N, Kessler M, Ladrière M, Morelon E, Buron F, Giral M, Dantan E.

Nephrol Dial Transplant. 2019 Apr 1;34(4):703-711. doi: 10.1093/ndt/gfy221.


Actinomycosis: An infrequent disease in renal transplant recipients?

Rousseau C, Piroth L, Pernin V, Cassuto E, Etienne I, Jeribi A, Kamar N, Pouteil-Noble C, Mousson C.

Transpl Infect Dis. 2018 Dec;20(6):e12970. doi: 10.1111/tid.12970. Epub 2018 Aug 11.


Longterm Risk of Solid Organ De Novo Malignancies After Liver Transplantation: A French National Study on 11,226 Patients.

Sérée O, Altieri M, Guillaume E, De Mil R, Lobbedez T, Robinson P, Segol P, Salamé E, Abergel A, Boillot O, Conti F, Chazouillères O, Debette-Gratien M, Debray D, Hery G, Dharancy S, Durand F, Duvoux C, Francoz C, Gugenheim J, Hardwigsen J, Houssel-Debry P, Jacquemin E, Kamar N, Latournerie M, Lebray P, Leroy V, Mazzola A, Neau-Cransac M, Pageaux GP, Radenne S, Saliba F, Samuel D, Vanlemmens C, Woehl-Jaegle ML, Launoy G, Dumortier J.

Liver Transpl. 2018 Oct;24(10):1425-1436. doi: 10.1002/lt.25310.


Sirolimus for Secondary Prevention of Skin Cancer in Kidney Transplant Recipients: 5-Year Results.

Dantal J, Morelon E, Rostaing L, Goffin E, Brocard A, Tromme I, Broeders N, Del Marmol V, Chatelet V, Dompmartin A, Kessler M, Serra A, Hofbauer GFL, Kamar N, Pouteil-Noble C, Kanitakis J, Roux A, Decullier E, Euvrard S; TUMORAPA Study Group.

J Clin Oncol. 2018 Sep 1;36(25):2612-2620. doi: 10.1200/JCO.2017.76.6691. Epub 2018 Jul 17.


Acute hepatitis E in French patients and neurological manifestations.

Abravanel F, Pique J, Couturier E, Nicot F, Dimeglio C, Lhomme S, Chiabrando J, Saune K, Péron JM, Kamar N, Evrard S, de Valk H, Cintas P, Izopet J; HEV study group.

J Infect. 2018 Sep;77(3):220-226. doi: 10.1016/j.jinf.2018.06.007. Epub 2018 Jul 10.


Diversity of hepatitis E virus genotype 3.

Nicot F, Jeanne N, Roulet A, Lefebvre C, Carcenac R, Manno M, Dubois M, Kamar N, Lhomme S, Abravanel F, Izopet J.

Rev Med Virol. 2018 Sep;28(5):e1987. doi: 10.1002/rmv.1987. Epub 2018 Jun 25.


Hepatitis E virus-associated cryoglobulinemia in solid-organ-transplant recipients.

Marion O, Abravanel F, Del Bello A, Esposito L, Lhomme S, Puissant-Lubrano B, Alric L, Faguer S, Izopet J, Kamar N.

Liver Int. 2018 Dec;38(12):2178-2189. doi: 10.1111/liv.13894. Epub 2018 Jun 14.


Impact of donor BK polyomavirus replication on recipient infections in living donor transplantation.

Grellier J, Hirsch HH, Mengelle C, Esposito L, Hebral AL, Bellière J, Weissbach F, Izopet J, Del Bello A, Kamar N.

Transpl Infect Dis. 2018 Aug;20(4):e12917. doi: 10.1111/tid.12917. Epub 2018 Jun 11.


Reply to: "Association of hepatitis E virus infection and myasthenia gravis: A pilot study".

van Eijk JJJ, Cintas P, Jacobs BC, Kamar N, Dalton HR.

J Hepatol. 2018 Jun;68(6):1321-1322. doi: 10.1016/j.jhep.2018.02.017. No abstract available.


Acute and Persistent Hepatitis E Virus Genotype 3 and 4 Infection: Clinical Features, Pathogenesis, and Treatment.

Kamar N, Pischke S.

Cold Spring Harb Perspect Med. 2018 May 7. pii: a031872. doi: 10.1101/cshperspect.a031872. [Epub ahead of print]


Grazoprevir plus elbasvir in HCV genotype-1 or -4 infected patients with stage 4/5 severe chronic kidney disease is safe and effective.

Alric L, Ollivier-Hourmand I, Bérard E, Hillaire S, Guillaume M, Vallet-Pichard A, Bernard-Chabert B, Loustaud-Ratti V, Bourlière M, de Ledinghen V, Fouchard-Hubert I, Canva V, Minello A, Nguyen-Khac E, Leroy V, Saadoun D, Trias D, Pol S, Kamar N.

Kidney Int. 2018 Jul;94(1):206-213. doi: 10.1016/j.kint.2018.02.019. Epub 2018 May 5.


High tacrolimus intra-patient variability is associated with graft rejection, and de novo donor-specific antibodies occurrence after liver transplantation.

Del Bello A, Congy-Jolivet N, Danjoux M, Muscari F, Lavayssière L, Esposito L, Hebral AL, Bellière J, Kamar N.

World J Gastroenterol. 2018 Apr 28;24(16):1795-1802. doi: 10.3748/wjg.v24.i16.1795.


Safety of sofosbuvir-based regimens after liver transplantation: longitudinal assessment of renal function in the prospective ANRS CO23 CUPILT study.

Anty R, Favre G, Coilly A, Rossignol E, Houssel-Debry P, Duvoux C, De Ledinghen V, Di Martino V, Leroy V, Radenne S, Kamar N, Canva V, D'Alteroche L, Durand F, Dumortier J, Lebray P, Besch C, Tran A, Canivet CM, Botta-Fridlund D, Montialoux H, Moreno C, Conti F, Silvain C, Perré P, Habersetzer F, Abergel A, Debette-Gratien M, Dharancy S, Esnault VLM, Fougerou-Leurent C, Cagnot C, Diallo A, Veislinger A, Danjou H, Samuel D, Pageaux GP, Duclos-Vallée JC; ANRS CO23 CUPILT Study Group.

Aliment Pharmacol Ther. 2018 Jun;47(12):1682-1689. doi: 10.1111/apt.14639. Epub 2018 Apr 17.


12 Weeks of a Ribavirin-Free Sofosbuvir and Nonstructural Protein 5A Inhibitor Regimen Is Enough to Treat Recurrence of Hepatitis C After Liver Transplantation.

Houssel-Debry P, Coilly A, Fougerou-Leurent C, Jezequel C, Duvoux C, De Ledinghen V, Radenne S, Kamar N, Leroy V, Martino VD, D'Alteroche L, Canva V, Conti F, Dumortier J, Montialoux H, Lebray P, Botta-Fridlund D, Tran A, Moreno C, Silvain C, Besch C, Perre P, Francoz C, Abergel A, Habersetzer F, Debette-Gratien M, Cagnot C, Diallo A, Chevaliez S, Rossignol E, Veislinger A, Duclos-Vallee JC, Pageaux GP; the ANRS CO23 CUPILT study group.

Hepatology. 2018 Oct;68(4):1277-1287. doi: 10.1002/hep.29918.


Conversion to Belatacept in Maintenance Kidney Transplant Patients: A Retrospective Multicenter European Study.

Darres A, Ulloa C, Brakemeier S, Garrouste C, Bestard O, Del Bello A, Sberro Soussan R, Dürr M, Budde K, Legendre C, Kamar N.

Transplantation. 2018 Sep;102(9):1545-1552. doi: 10.1097/TP.0000000000002192.


Direct-acting antivirals and hepatitis B virus (HBV) reactivation in co-infected HBV/HCV kidney-transplant recipients.

Pol S, Marion O, Vallet-Pichard A, Meritet JF, Sauné K, Alric L, Kamar N.

Transpl Infect Dis. 2018 Jun;20(3):e12864. doi: 10.1111/tid.12864. Epub 2018 Mar 25.


Pharmacokinetic Therapeutic Drug Monitoring of Advagraf in More Than 500 Adult Renal Transplant Patients, Using an Expert System Online.

Marquet P, Bedu A, Monchaud C, Saint-Marcoux F, Rérolle JP, Etienne I, Kamar N, Moulin B, Cassuto E, Essig M, Woillard JB.

Ther Drug Monit. 2018 Jun;40(3):285-291. doi: 10.1097/FTD.0000000000000503.


Dosing ribavirin in hepatitis E-infected solid organ transplant recipients.

De Winter BCM, Hesselink DA, Kamar N.

Pharmacol Res. 2018 Apr;130:308-315. doi: 10.1016/j.phrs.2018.02.030. Epub 2018 Feb 27. Review.


Eculizumab for Thrombotic Microangiopathy Associated with Antibody-Mediated Rejection after ABO-Incompatible Kidney Transplantation.

Lanfranco L, Joly M, Del Bello A, Esposito L, Cognard N, Perrin P, Moulin B, Kamar N, Caillard S.

Case Rep Transplant. 2017;2017:3197042. doi: 10.1155/2017/3197042. Epub 2017 Dec 28.


Schistosomiasis and Strongyloidiasis Recommendations for Solid-Organ Transplant Recipients and Donors.

Camargo LFA, Kamar N, Gotuzzo E, Wright AJ.

Transplantation. 2018 Feb;102(2S Suppl 2):S27-S34. doi: 10.1097/TP.0000000000002016. Review. No abstract available.


The authors reply.

Faguer S, Kamar N, Cointault O.

Crit Care Med. 2018 Feb;46(2):e177-e178. doi: 10.1097/CCM.0000000000002858. No abstract available.


Propensity score-based comparison of the graft failure risk between kidney transplant recipients of standard and expanded criteria donor grafts: Toward increasing the pool of marginal donors.

Querard AH, Le Borgne F, Dion A, Giral M, Mourad G, Garrigue V, Rostaing L, Kamar N, Loupy A, Legendre C, Morelon E, Buron F, Foucher Y, Dantan E.

Am J Transplant. 2018 May;18(5):1151-1157. doi: 10.1111/ajt.14651. Epub 2018 Feb 8.


Dynamic Prognostic Score to Predict Kidney Allograft Survival in Patients with Antibody-Mediated Rejection.

Viglietti D, Loupy A, Aubert O, Bestard O, Duong Van Huyen JP, Taupin JL, Glotz D, Legendre C, Jouven X, Delahousse M, Kamar N, Lefaucheur C.

J Am Soc Nephrol. 2018 Feb;29(2):606-619. doi: 10.1681/ASN.2017070749. Epub 2017 Dec 18.

Supplemental Content

Support Center